GlaxoSmithKline is axing around 350 jobs in research and development as part of an ongoing restructuring program, Europe's biggest drugmaker said on Wednesday. The sites affected include three in the United States -- Research Triangle Park, Upper Providence and Upper Merion -- as well as Harlow in Britain and Verona in Italy.
More
No comments:
Post a Comment